HC Wainwright & Co. Reiterates Buy on TuHURA Biosciences, Maintains $10 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates TuHURA Biosciences (NASDAQ:HURA) with a Buy and maintains $10 price target.
Last updated: 2026-11-17 16:32:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
TuHURA Biosciences, Inc. (HURA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.37, with a market capitalization of $88.58M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.41 to $3.43. This page covers its latest market performance, valuation, price trends and company information.
$88.58M | |
$1.30 | |
$1.44 | |
$1.30 | |
$1.33 | |
145.31K | |
321.91K | |
-- | |
$3.43 | |
$0.41 | |
0.01% | |
-- |
TuHURA Biosciences, Inc. (HURA) is currently trading at $1.37 as of 2026-11-17 16:31:00, up 6.39% ($0.08) from the previous close of $1.33
During today's regular trading session, HURA has traded between $1.30 and $1.44, with a trading volume of 145.31K shares. The current price is near the middle of today's range.
Over the past seven days, TuHURA Biosciences, Inc. (HURA) moved from $1.63 to $1.37, representing a decline of 16.26% ($0.26).
The stock traded between $1.27 and $1.75 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 593.59 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 31.6%
HURA is currently trading at $1.37, placing it 31.6% of the way from its 52-week low of $0.41 to its 52-week high of $3.43. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 22 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to TuHURA Biosciences, Inc. and HURA stock.
HC Wainwright & Co. analyst Robert Burns reiterates TuHURA Biosciences (NASDAQ:HURA) with a Buy and maintains $10 price target.
TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.14) by 23.08 percent. This is a 28.57 percent increase over losses of $(0.14) per share
Eligible investors can buy real shares of TuHURA Biosciences, Inc. (HURA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to HURA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between HURA shares and USD.
HURA Shares to USD
1.00 HURA shares = 1.365 USD
Calculations are estimates based on the latest available price and are for reference only.